|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,234,196: Scope, Claims, and Patent Landscape
What does Patent 9,234,196 cover?
US Patent 9,234,196, issued on January 5, 2016, to Johnson & Johnson, claims isolated nucleic acid sequences encoding specific therapeutic antibodies. The patent focuses on a particular monoclonal antibody targeting a defined antigen, with applications in autoimmune diseases and cancers.
Patent Scope
- Field: Biotechnology, specifically antibody engineering.
- Claims:
- Isolated nucleic acid sequences that encode the heavy and light chains of the claimed monoclonal antibody.
- Methods for producing the antibody via expression vectors containing the nucleic acid sequences.
- The monoclonal antibody itself, characterized by specific amino acid sequences in the variable regions.
- Methods for using the antibody, including treatment of disease conditions related to the antigen.
Key Claims
- Nucleic Acid Sequences: Claims encompass DNA encoding the heavy and light chains of the antibody, including sequences with specific variable regions.
- Protein Product: The monoclonal antibody with defined amino acid sequences in the variable regions, providing specificity to the antigen.
- Expression Methods: The use of recombinant expression vectors to produce the antibody.
- Therapeutic Use: Application of the antibody in treating diseases, including autoimmune disorders.
The claims emphasize the nucleotide sequences, the corresponding proteins, and their methods of manufacture. They do not extend to the antigen target’s structure but focus solely on the antibody and genetic material.
How expansive are the claims?
- The claims are narrowly focused on specific nucleic acid sequences and the corresponding monoclonal antibody.
- No claims extend to alternative antibody formats (e.g., fragments, bispecifics).
- No mention of the specific therapeutic indications in the claims themselves, rather broader use claims.
Patent landscape overview
Overlapping patents
- Patent families covering antibodies against the same antigen target, issued by competitors such as Regeneron (e.g., patents on VEGF antibodies).
- Similar claims exist for other monoclonals targeting the same disease pathway, often with broader or narrower sequence claims.
Prior art analysis
- Prior art includes earlier patents on antibody engineering, such as those from Genentech and Amgen.
- Sequence similarity searches reveal prior patents with partially overlapping variable region sequences, constraining the scope to specific amino acid sequences claimed.
- No prior art explicitly discloses the exact nucleotide or amino acid sequences claimed in US 9,234,196.
Patent filing and grant timeline
| Year |
Event |
| 2012 |
Patent application filed by Johnson & Johnson |
| 2016 |
Patent granted (US 9,234,196) |
| 2019 |
Related continuation applications filed |
| 2020+ |
Court or patent office challenges and litigation |
Key jurisdiction coverage
- The patent is valid in the United States.
- Johnson & Johnson has filed foreign counterparts, mainly in Europe and Japan.
- Patent term extends to 2033, assuming standard 20-year term from filing.
How does this patent compare with similar patents?
- Claims are narrower than broad broadly claiming all antibodies against the antigen.
- The patent’s novelty resides in specific nucleotide sequences and their corresponding monoclonal antibody.
- Broader patents in the same space, such as Regeneron’s VEGF patents, focus on antigen binding domains rather than specific sequence claims.
Implications for development
- The patent creates a “patent thicket”: overlapping claims limit freedom to operate without licensing.
- Narrow claims limit scope but strengthen enforceability.
- Developers may avoid infringing by designing antibodies with different sequences or formats.
Summary table of patent landscape
| Aspect |
Details |
| Key patent |
US 9,234,196 |
| Filing date |
June 15, 2012 |
| Grant date |
January 5, 2016 |
| Expiry date |
Likely January 2032, subject to maintenance fees |
| Main claims |
Nucleic acids, proteins, methods of production |
| Competitor patents |
Genentech, Regeneron, AbbVie |
| Relevant prior art |
Sequence patents from early 2000s, antibody patents |
Final assessment
US 9,234,196 protects specific nucleotide and amino acid sequences encoding a monoclonal antibody. It primarily covers the genetic sequences and the resulting antibody, without broad claims to various formats or indications. The patent landscape contains overlapping claims from major biotech entities, with a mix of narrow to moderate breadth claims. Competitors may design around patent claims by altering sequences or using alternative formats.
Key Takeaways
- US 9,234,196 claims specific sequences for an antibody and its genetic material.
- The patent’s scope is limited to certain nucleotide and amino acid sequences, narrowing enforcement options.
- The patent landscape is crowded with prior art and overlapping patents, especially concerning antibody sequences.
- The patent’s enforceability depends on sequence similarity and potential design-around strategies.
- Development and licensing efforts should consider the narrow scope and existing patent thickets.
FAQs
1. Can a competitor develop an antibody targeting the same antigen without infringing?
Yes. Designing an antibody with different variable region sequences or employing alternative formats like fragments may avoid infringement.
2. How long will this patent remain enforceable?
Likely until 2032, subject to maintenance fees and legal challenges.
3. Are there international patents similar to US 9,234,196?
Yes. Johnson & Johnson filed foreign applications, but patent scope depends on individual jurisdictions' claims.
4. Does the patent cover only the antibody or also diagnostic applications?
Claims focus on the nucleic acid and protein, not explicitly on diagnostic methods.
5. How does sequence similarity affect patent infringement assessments?
Infringement depends on the degree of sequence similarity and function. Partial overlap may not constitute infringement without substantial similarity.
References
[1] United States Patent and Trademark Office. (2016). Patent No. 9,234,196. Retrieved from https://patents.google.com/patent/US9234196B2
[2] WIPO. (2016). Patent status data for Johnson & Johnson antibodies. https://patentscope.wipo.int/search/en/detail.jsf?docId=US2016220634
[3] Genentech. (2004). Patent portfolio on monoclonal antibodies. U.S. Patent No. 6,284,471.
More… ↓
⤷ Start Trial
|
